A Clinical Trial to Evaluate the Efficacy and Safety of a Spot Stent System Used in Femoropopliteal Arteries.

Inclusion Criteria: * Age ≥18 years old and ≤80 years old * Had lower extremity arterial occlusive diseases, and Rutherford classification is 2-5 * Target lesion is in the superficial femoral artery (SFA) and/or proximal popliteal artery (above the knee), located ≥1 cm below the common femoral artery (CFA) bifurcation to the distal segment of the proximal popliteal artery at the superior end of the patella. * Target lesion had severe stenosis (stenosis degree ≥70%) or occlusion. * Presence of at least one patent infrapopliteal vessel. * The length of target lesion ≥10 cm. * After predilation, the target lesion has \<30% residual stenosis and presence of at least one flow-limiting dissection (by visual estimate). * Subject (or legal guardian) understands the study requirements and procedures and provides written Informed Consent before any study tests or procedures are performed. Exclusion Criteria: * The plasma creatinine level is higher than 150 umol/L. * Thrombolysis or thrombectomy is required. * The patient had underwent lower-limb arterial surgery or thrombolysis on the target limb within 6 weeks. * Previously implanted stent in the target lesion. * The guide wire can not cross the target lesion. * Angiographic evidence of calcification severe enough that it renders the target lesion non-dilatable. * Patient has a known allergy to anticoagulant drugs, anti-platelet drugs or contrast medium that cannot be adequately pre-medicated. * Women who are pregnant or breast-feeding. * The subjects have participated in other drug property studies or device studies that have not yet completed the main end point. * Patient has life expectancy of less than 12 months. * Patient who planned to do above the ankle amputation before the operation. * Patient who had severe hemorrhage or coagulation disorder which judged by the investigator. * The investigator think the patient is not suitable for participation in the clinical trial.